reports
THEON signs the largest contract ever for 100,000 NVGs with OCCAR, val...
THEON signs the largest contract ever for 100,000 NVGs with OCCAR, valued at c.€1 billion PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS) Contract Revision for a firm order of 100,000 NVGs for the German BundeswehrPlus partial exercise of existing OCCAR option by the Belgian Armed Forces for 4,000 NVGsImmediate c.€1 bn increase to backlog, providing significant visibility until 2029Total backlog, including options, now c.€2.4 bn more than 2x vs Year End 2024 10 December 2025 – is pleased to announce the signing of a Contract Revision between OCCAR and THEON/Hensoldt consortium,...
Colliers partners with Google Cloud to accelerate digital and AI-power...
Colliers partners with Google Cloud to accelerate digital and AI-powered innovation One of the first in the industry to enter partnership through multi-million-dollar cloud technology investment TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Global diversified professional services and investment management company, Colliers (NASDAQ and TSX: CIGI), today announced its partnership to innovate with Google Cloud. As a pillar of Colliers’ multi-year technology transformation strategy, the migration to Google Cloud will unlock advanced analytics and AI for new product development and integrated ...
Weekly share repurchase program transaction details
Weekly share repurchase program transaction details Amsterdam, December 10, 2025 SBM Offshore reports the transaction details related to its EUR141 million (c. US$150 million1) share repurchase program for the period December 4, 2025 through December 10, 2025. The repurchases were made under the EUR141 million share repurchase program announced on February 20, 2025 and effective from April 24, 2025. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share ...
Euronext announces December 2025 quarterly review results of the PSI®
Euronext announces December 2025 quarterly review results of the PSI® Lisbon – 10 December 2025 Euronext today announced the results of the annual review for the PSI®, which will be implemented after markets close on Friday 19 December 2025 and will be effective from Monday 22 December 2025. Results of the December 2025 quarterly review PSI® No changes in the composition of the index The Independent Supervisor retains the right to change the published selection, for instance in the case of a removal due to a takeover, until the publication of the final data after close of Wednesday 17 ...
Transaction in Own Shares
Transaction in Own Shares Transaction in Own Shares 10 December, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 10 December, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchaseNumber of Shares purchasedHighest price paid Lowest price paid Volume weighted average price paid per shareVenueCurrency10/12/2025757,62327.390027.085027.2388LSEGBP10/12/2025----Chi-X (CXE)GBP10/12/2025----BATS (BXE)GBP10/12/2025750,13431.410031.100031.2671XAMSEUR10/12/202...
Socfinasia: 1 director
A director at Socfinasia bought 14,523 shares at 24.000EUR and the significance rating of the trade was 86/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Elmos Semiconductor SE: 1 director
A director at Elmos Semiconductor SE sold 400 shares at 102.050EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Eik fasteignafélag hf.: Fjárhagsdagatal 2026
Eik fasteignafélag hf.: Fjárhagsdagatal 2026 Eik fasteignafélag hf. stefnir að birtingu árs- og árshlutauppgjöra ásamt aðalfundi á eftirfarandi dagsetningum: 5. febrúar 2026 – Stjórnendauppgjör 2025 og áætlun 2026 12. mars 2026 – Ársuppgjör, ársskýrsla og sjálfbærniskýrsla 2025 16. apríl 2026 – Aðalfundur 2026 7. maí 2026 – 1. ársfjórðungur 2026 18. ágúst 2026 – 2. ársfjórðungur 2026 5. nóvember 2026 – 3. ársfjórðungur 2026 4. febrúar 2027 – Stjórnendauppgjör 2026 og áætlun 2027 5. mars 2027 – Ársuppgjör, ársskýrsla og sjálfbærniskýrsla 2026 Birting fjárhagsupplýsinga mun eiga sér ...
Compagnie Financière Tradition S.A.: 1 director
A director at Compagnie Financière Tradition S.A. sold 501 shares at 287.108CHF and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Invesco Bond Income Plus: 1 director
A director at Invesco Bond Income Plus bought 20,010 shares at 175p and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate t...
EssilorLuxottica joins forces with Fondazione Chips-IT to accelerate the future of smart eyewear EssilorLuxottica joins forces with Fondazione Chips-ITto accelerate the future of smart eyewear Paris, France (10 December 2025) – EssilorLuxottica announces it is joining forces with Fondazione Chips-IT, Italy’s research center specializing in advanced integrated-circuit design, during today’s presentation of the foundation’s 2026-2028 strategic plan. This collaboration aims to further strengthen the Group’s leadership in smart eyewear by advancing application-specific chip development within...
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélér...
EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées EssilorLuxottica va collaborer avec la fondation Chips-IT pour accélérer dans les lunettes connectées Paris, France (10 décembre 2025) – EssilorLuxottica a annoncé aujourd'hui une collaboration avec la fondation Chips-IT, un centre italien de recherche spécialisé dans la conception avancée de circuits intégrés, à l’occasion de la présentation du plan stratégique 2026-2028 de la fondation. Cette collaboration vise à renforcer la position d'EssilorLuxottica dans les lunettes connectées en fa...
EssilorLuxottica annuncia l’avvio di una collaborazione con Fondazione...
EssilorLuxottica annuncia l’avvio di una collaborazione con Fondazione Chips-IT e accelera sugli smart glasses del futuro EssilorLuxottica annuncia l’avvio di una collaborazione con Fondazione Chips-IT e accelera sugli smart glasses del futuro Parigi, Francia (10 dicembre 2025) – EssilorLuxottica ha annunciato l’avvio di una collaborazione con Fondazione Chips-IT, centro di ricerca italiano specializzato nella progettazione avanzata di circuiti integrati, in occasione della presentazione del piano strategico 2026-2028 della fondazione. La partnership rafforza ulteriormente la leadership ...
Information sur les droits de vote et les actions au 30 novembre 2025
Information sur les droits de vote et les actions au 30 novembre 2025 Le 10 décembre 2025 Information relative au nombre total de droits de vote et d’actions composant le capital social Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation : Euronext Paris Compartiment : Compartiment ACode ISIN : FR0000054470Site web : Information mensuelle au 30 novembre 2025(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers) DateNombre total d’actions composan...
Bloober Team S.A.: 1 director
A director at Bloober Team S.A. bought 67,500 shares at 16.500PLN and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Log-In Logistica Intermodal Sa: 1 director
A director at Log-In Logistica Intermodal Sa sold 103,389 shares at 34.247BRL and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
COMPAGNIE LEBON : Transactions sur actions propres novembre 2025
COMPAGNIE LEBON : Transactions sur actions propres novembre 2025 PROGRAMME DE RACHAT Ce formulaire constitue l'annexe 3 de l'instruction AMF n° 2005-06 relative aux modalités de déclaration des programmes de rachat des actions propres et des opérations de stabilisationSIREN :552018731 LEI :969500Q0TXUSFDLH3940Dénomination sociale de l'émetteur :LEBON Nature des titres (nom du titre + caractéristiques : ADP, CCI…)actions Date de début du programme 21/05/2025 TABLEAU DE DECLARATION MENSUELLE DES OPERATIONS REALISEESPAR UN EMETTEUR SUR SES PROPRES TITRES...
COMPAGNIE LEBON : Capital et droits de vote novembre 2025
COMPAGNIE LEBON : Capital et droits de vote novembre 2025 Middle Office Emetteur Tél. : 01 53 48 80 10 - Fax : 01 49 74 32 77 - COMPAGNIE LEBON Date d'arrêté:30/11/2025 ARTICLE 223-16 du règlement général de l'AMF Actions du capital 1 173 000 Droits de vote théoriques (1) 2 126 108 Actions privées de droits de vote Autodétention au nominatif (2) 44 815 Autodétention au porteur * (3) 0 Autres * (4) 0 * à compléter par la société Droits de vote exerçables* 2 081 293 *= (1) - [(2) + (3) + (4)] Pour information : Nombre de Comptes Courants Nominatifs 2 034 Pièc...
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Thera...
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a potential new therapeutic approach for difficult-to-treat cancers: No dose limiting toxicity reached to date, enabling recruitment of a third patient cohortGNS561 and MEKi combination demonstrated disease stabilization in all evaluable patients with evidence of tumor shrinkage in a subset of patients, warrant...
GENFIT : GNS561 montre une activité antitumorale prometteuse en combin...
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique Données préliminaires très encourageantes de l’étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, positionnant cette combinaison innovante comme une nouvelle approche thérapeutique potentielle pour les cancers difficiles à traiter : Pas de toxicité dose-limitante observée à ce jour, permettant la poursuite du recrutement d’une troisième cohorte de patientsLa combinaison GNS561 + MEKi a démontré...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.